Dr. Mikhail Blagosklonny is an Oncologist who researches cancer and aging and is also a professor at the Roswell Park Cancer Institute in Buffalo, New York. He attended the First Pavlov State Medical University of St. Petersburg where he received both his M.D. for Internal Medicine and a Ph.D. in Cardiology and Experimental Medicine. Prior to his Work at Roswell Park Cancer Institute he was an Associate Professor of Medicine at New York Medical College.
Dr. Blagosklonny teaches Oncology at Roswell Park Cancer Institute. Oncology is a branch of medicine that is focused on tumors and cancers. He teaches his students about how to diagnose cancer, grading how aggressive it is, and how to decide on the best treatments for patients. He teaches how to perform a biopsy of tumorous tissue and use diagnostic tools such as CT and MRI scanning, Scintigraphy, Positron Emission Tomography, and Nuclear Medicine techniques.
The research that Dr. Blagosklonny engages in ranges from cellular and molecular biology as well as clinical investigations. He has worked on new anticancer scientific strategies like exploiting cancer cell cycling. He has extended this research into developing therapies for other age-related diseases and even aging itself and is a prominent proponent of using the cancer drug Rapamycin to stop the aging process. To date he has published over 300 articles in peer-reviewed journals and has been cited in over 25,000 other articles.
One of the journals that Dr. Mikhail Blagosklonny has been heavily involved with is Oncotarget which he co-founded and is co-editor in chief of. While Oncotarget has been focused on the field of Oncology it has recently branched out to include other several other medical specialties like Cardiology, Metabolism, Neuroscience, Pharmacology, and Cell Biology. The goal is to bring together disciplines and eliminate the border that has generally separated them in the past. The online journal is also dedicated to making scientific research widely and rapidly available in order to advance medicine. Among the other journals that he has founded and/or served as editor-in-chief of are Cell Cycle, Oncoscience, and Aging. View his LinkedIn profile.